Crossmark

Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase

Crossref DOI link: https://doi.org/10.1007/s12032-018-1093-8

Published Online: 2018-02-13

Published Print: 2018-03

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Tokuhira, Michihide https://orcid.org/0000-0003-3780-5331
Kimura, Yuta

Sugimoto, Keiji

Nakazato, Tomonori

Ishikawa, Maho

Fujioka, Isao

Takaku, Tomoiku

Iriyama, Noriyoshi

Sato, Eriko

Fujita, Hiroyuki

Hatta, Yoshihiro

Komatsu, Norio

Asou, Norio

Kizaki, Masahiro

Kawaguchi, Tatsuya
License Information

Text and Data Mining valid from 2018-02-13
More Information

Article History

Received: 30 December 2017

Accepted: 31 January 2018

First Online: 13 February 2018

Compliance with ethical standards

:

: MT received honoraria from Pfizer Inc. and Bristol-Myers Squibb. TT, NI, YH, MK, and TK received honoraria from Bristol-Myers Squibb and Novartis Pharma K.K. The remaining authors declare no competing financial interests.

: All procedures performed in studies were in accordance with the ethical standards of each institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

: Informed consent was obtained from all individual participants included in the study.